antitumor effect

Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.

BAT1006 is a monoclonal antibody targeting the extracellular domain II of HER2, with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). It is utilized for research in HER2-positive locally advanced/metastatic solid tumors. Compared to pertuzumab, BAT1006 exhibits roughly 5 times increased ADCC effect and demonstrates potent antitumor activity in HER2-positive Calu-3 xenograft mouse models.